Use of Respimat Soft Mist Inhaler in COPD Patients

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2007 Dec 1

PMID 18046862

Citations 42

Authors

Paula Anderson

Affiliations

Soon will be listed here.

Abstract

Events of the past decade have stimulated development of new drug formulations and delivery devices that have improved the efficiency, ease of use, and environmental impact of inhaled drug therapy. Respimat Soft Mist Inhaler is a novel, multidose, propellant-free, hand-held, liquid inhaler that represents a new category of inhaler devices. The aerosol cloud generated by Respimat contains a higher fraction of fine particles than most pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs), and the aerosol spray exits the inhaler more slowly and for a longer duration than with pMDIs. This translates into higher lung drug deposition and lower oropharyngeal deposition, making it possible to give lower nominal doses of delivered drugs without lowering efficacy. In clinical trials in patients with COPD, bronchodilator drugs delivered from Respimat were equally effective at half of the dose delivered from a pMDI. In one study of inhaler preference, Respimat was preferred over the pMDI by patients with COPD and other obstructive lung diseases. Respimat is a valuable addition to the range of inhaler devices available to the patient with COPD.

Citing Articles

The Need to Emphasize Inhaler Education in Residency and Fellowship Training in the Era of Climate Change.

Yeo A, Lui J J Grad Med Educ. 2024; 16(6 Suppl):19-21.

PMID: 39677908 PMC: 11644589. DOI: 10.4300/JGME-D-24-00073.1.

Usability of inhaler devices: a parameter currently misused.

Dal Negro R Multidiscip Respir Med. 2024; 19.

PMID: 38577745 PMC: 10968837. DOI: 10.5826/mrm.2024.960.

Storage stability of lysostaphin solution and its pulmonary delivery.

Zeng P, Zhang P, Chan H, Chow S, Lam J, Ip M Drug Deliv Transl Res. 2024; 14(9):2433-2443.

PMID: 38231385 PMC: 11291608. DOI: 10.1007/s13346-024-01518-9.

Aerosol Plumes of Inhalers Used in COPD.

Wachtel H, Emerson-Stadler R, Langguth P, Hohlfeld J, Ohar J Pulm Ther. 2024; 10(1):109-122.

PMID: 38194194 PMC: 10881950. DOI: 10.1007/s41030-023-00249-5.

Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines.

Puri M, Miranda-Hernandez S, Subbian S, Kupz A Front Immunol. 2023; 14:1159084.

PMID: 37063870 PMC: 10098179. DOI: 10.3389/fimmu.2023.1159084.

References

Goldberg J, Freund E, Beckers B, Hinzmann R . Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler. Eur Respir J. 2001; 17(2):225-32. DOI: 10.1183/09031936.01.17202250. View

Hodder R, Pavia D, Dewberry H, Alexander K, Iacono P, Ponitz H . Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler. Respir Med. 2005; 99(9):1087-95. DOI: 10.1016/j.rmed.2005.03.037. View

Newman S, Brown J, Steed K, Reader S, Kladders H . Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest. 1998; 113(4):957-63. DOI: 10.1378/chest.113.4.957. View

Dalby R, Spallek M, Voshaar T . A review of the development of Respimat Soft Mist Inhaler. Int J Pharm. 2004; 283(1-2):1-9. DOI: 10.1016/j.ijpharm.2004.06.018. View

Vincken W, Bantje T, Middle M, Gerken F, Moonen D . Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat((R)) Soft Misttrade mark Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma. Clin Drug Investig. 2007; 24(1):17-28. DOI: 10.2165/00044011-200424010-00003. View

FINK J . Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care. 2000; 45(6):623-35. View

Kozma C, Slaton T, Monz B, Hodder R, Reese P . Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med. 2005; 4(1):41-52. DOI: 10.2165/00151829-200504010-00005. View

Melani A, Zanchetta D, Barbato N, Sestini P, Cinti C, Canessa P . Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004; 93(5):439-46. DOI: 10.1016/s1081-1206(10)61410-x. View

Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H . Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005; 18(3):273-82. DOI: 10.1089/jam.2005.18.273. View

10.

WILKES W, Fink J, Dhand R . Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J Aerosol Med. 2001; 14(3):351-60. DOI: 10.1089/089426801316970312. View

11.

Koehler D, Pavia D, Dewberry H, Hodder R . Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat Soft Mist inhaler: results of phase II single-dose crossover studies. Respiration. 2004; 71(5):469-76. DOI: 10.1159/000080631. View

12.

Kilfeather S, Ponitz H, Beck E, Schmidt P, Lee A, Bowen I . Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir Med. 2004; 98(5):387-97. DOI: 10.1016/j.rmed.2003.12.007. View

13.

Newman S, Weisz A, Talaee N, Clarke S . Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991; 46(10):712-6. PMC: 463388. DOI: 10.1136/thx.46.10.712. View

14.

van Noord J, Smeets J, Creemers J, Greefhorst L, Dewberry H, CORNELISSEN P . Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler. a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients. Respiration. 2000; 67(6):672-8. DOI: 10.1159/000056298. View

15.

Iacono P, Velicitat P, Guemas E, Leclerc V, Thebault J . Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respir Med. 2000; 94(5):490-5. DOI: 10.1053/rmed.1999.0770. View

16.

Wolff R, Niven R . Generation of aerosolized drugs. J Aerosol Med. 1993; 7(1):89-106. DOI: 10.1089/jam.1994.7.89. View

17.

Newman S, Steed K, Reader S, Hooper G, Zierenberg B . Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996; 85(9):960-4. DOI: 10.1021/js950522q. View

18.

Dolovich M, Ahrens R, Hess D, Anderson P, Dhand R, Rau J . Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005; 127(1):335-71. DOI: 10.1378/chest.127.1.335. View

19.

Vincken W, Dewberry H, Moonen D . Fenoterol delivery by Respimat soft mist inhaler versus CFC metered dose inhaler: cumulative dose-response study in asthma patients. J Asthma. 2003; 40(6):721-30. DOI: 10.1081/jas-120023495. View

20.

Zierenberg B . Optimizing the in vitro performance of Respimat. J Aerosol Med. 2000; 12 Suppl 1:S19-24. DOI: 10.1089/jam.1999.12.suppl_1.s-19. View